Читать книгу The Esophagus - Группа авторов - Страница 64

1 1 Ford AC, Suares NC, Talley NJ. Meta‐analysis: the epidemiology of noncardiac chest pain in the community. Aliment Pharmacol Ther 2011; 34:172–180.

2 2 Riley R, Miller C, Russell G, et al. Cost analysis of the HEART pathway randomized control trial. Am J Emerg Med 2017; 35:77–81.

3 3 Haasenritter J, Biroga T, Keunecke C, et al. Causes of chest pain in primary care – a systematic review and meta‐analysis. Croat Med J 2015; 56:422–430.

4 4 Niska R, Bhuiya F, Xu J. National hospital ambulatory medical care survey: 2007 emergency department summary tables. Natl Heal Stat Rep 2011:1–32.

5 5 Dabhadkar K, Maan A. National trends in admissions for chest pain evaluation: 2006–2013. J Am Coll Cardiol 2017; 69:286.

6 6 Chambers JB, Marks EM, Hunter MS. The head says yes but the heart says no: what is non‐cardiac chest pain and how is it managed? Heart 2015; 101:1240–1249.

7 7 Buntinx F, Knockaert D, de Blaey N, et al. Chest pain in general practice or in the hospital emergency department: is it the same? Fam Pract 2002; 18:586–589.

8 8 Svavarsdóttir AE, Jónasson MR, Gudmundsson GH, et al. Chest pain in family practice: Diagnosis and long‐term outcome in a community setting. Can Fam Physician 1996; 42:1672.

9 9 Klinkman MS, Stevens D, Gorenflo DW. Episodes of care for chest pain: a preliminary report from MIRNET. Michigan Research Network. J Fam Pract 1994; 38:345–352.

10 10 Bösner S, Becker A, Haasenritter J, et al. Chest pain in primary care: Epidemiology and pre‐work‐up probabilities. Eur J Gen Pract 2009; 15:141–146.

11 11 Ebell MH. Evaluation of chest pain in primary care patients. Am Fam Physician 2011; 83:603–605.

12 12 Hoorweg BBN, Willemsen RTA, Cleef LE, et al. Frequency of chest pain in primary care, diagnostic tests performed and final diagnoses. Heart 2017; 103:1727–1732.

13 13 Hsia RY, Hale Z, Tabas JA. A national study of the prevalence of life‐threatening diagnoses in patients with chest pain. JAMA Intern Med 2016; 176:1029.

14 14 Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population‐based study in Olmsted County, Minnesota. Gastroenterology 1997; 112:1448–1456.

15 15 Eslick GD, Jones MP, Talley NJ. Non‐cardiac chest pain: prevalence, risk factors, impact and consulting ‐ a population‐based study. Aliment Pharmacol Ther 2003; 17:1115–1124.

16 16 Chiocca J, Olmos J, Salis G, et al. Prevalence, clinical spectrum and atypical symptoms of gastro‐oesophageal reflux in Argentina: a nationwide population‐based study. Aliment Pharmacol Ther 2005; 22:331–342.

17 17 Wong WM, Lai KC, Lam KF, et al. Prevalence, clinical spectrum and health care utilization of gastro‐oesophageal reflux disease in a Chinese population: a population‐based study. Aliment Pharmacol Ther 2003; 18:595–604.

18 18 Tew R, Guthrie EA, Creed FH, et al. A long‐term follow‐up study of patients with ischaemic heart disease versus patients with nonspecific chest pain. J Psychosom Res 1995; 39:977–985.

19 19 Mudipalli RS, Remes‐Troche JM, Andersen L, et al. Functional Chest Pain. J Clin Gastroenterol 2007; 41:264–269.

20 20 Clouse RE, Lustman PJ. Psychiatric illness and contraction abnormalities of the esophagus. N Engl J Med 1983; 309:1337–1342.

21 21 Fleet RP, Dupuis G, Marchand A, et al. Panic disorder in emergency department chest pain patients: Prevalence, comorbidity, suicidal ideation, and physician recognition. Am J Med 1996; 101:371–380.

22 22 Kahn SE. The challenge of evaluating the patient with chest pain. Arch Pathol Lab Med 2000; 124:1418–1419.

23 23 Demeester T, O’Sullivan G, Bermudez G, et al. Esophageal function in patients with angina‐type chest pain and normal coronary angiograms. Ann Surg 1982; 196:488–498.

24 24 Hewson, EG, Sinclair JW, Dalton CB, et al. Twenty‐four‐hour esophageal pH monitoring: The most useful test for evaluating noncardiac chest pain. Am J Med 1991; 90:576–583.

25 25 Rosztóczy A, Vass A, Izbéki F, et al. The evaluation of gastro‐oesophageal reflux and oesophagocardiac reflex in patients with angina‐like chest pain following cardiologic investigations. Int J Cardiol 2007; 118:62–68.

26 26 Singh S. The contribution of gastroesophageal reflux to chest pain in patients with coronary artery disease. Ann Intern Med 1992; 117:824.

27 27 Richter JE, Hewson EG, Sinclair JW, et al. Acid perfusion test and 24–hour esophageal pH monitoring with symptom index. Dig Dis Sci 1991; 36:565–571.

28 28 Chauhan A, Mullins PA, Taylor G, et al. Cardioesophageal reflex: A mechanism for “linked angina” in patients with angiographically proven coronary artery disease. J Am Coll Cardiol 1996; 27:1621–1628.

29 29 Hu WHC, Martin CJ, Talley NJ. Intraesophageal acid perfusion sensitizes the esophagus to mechanical distension: a Barostat study. Am J Gastroenterol 2000; 95:2189–2194.

30 30 Achem SR, Kolts BE, MacMath T, et al. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci 1997; 42:2138–2145.

31 31 Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998; 115:42–49.

32 32 Ofman JJ, Gralnek IM, Udani J, et al. The cost‐effectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med 1999; 107:219–227.

33 33 Xia HHX, Lai KC, Lam SK, et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy‐negative patients with non‐cardiac chest pain. Aliment Pharmacol Ther 2003; 17:369–377.

34 34 Dickman R, Emmons S, Cui H, et al. The effect of a therapeutic trial of high‐dose rabeprazole on symptom response of patients with non‐cardiac chest pain: a randomized, double‐blind, placebo‐controlled, crossover trial. Aliment Pharmacol Ther 2005; 22:547–555.

35 35 Kim JH, Sinn DH, Son HJ, et al. Comparison of one‐week and two‐week empirical trial with a high‐dose rabeprazole in non‐cardiac chest pain patients. J Gastroenterol Hepatol 2009; 24:1504–1509.

36 36 Cremonini F, Wise J, Moayyedi P, et al. Diagnostic and therapeutic use of proton pump inhibitors in non‐cardiac chest pain: a metaanalysis. Am J Gastroenterol 2005; 100:1226–1232.

37 37 Wang WH, Huang JQ, Zheng GF, et al. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with non‐cardiac chest pain? Arch Intern Med 2005; 165:1222.

38 38 Richter JE, Pandolfino JE, Vela MF, et al. Utilization of wireless pH monitoring technologies: A summary of the proceedings from the Esophageal Diagnostic Working Group. Dis Esophagus 2013; 26:755–765.

39 39 Bredenoord AJ, Weusten BLAM, Timmer R, et al. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy. Am J Gastroenterol 2006; 101:453–459.

40 40 Prakash C, Clouse RE. Wireless pH monitoring in patients with non‐cardiac chest pain. Am J Gastroenterol 2006; 101:446–452.

41 41 Tseng D, Rizvi AZ, Fennerty MB, et al. Forty‐eight‐hour pH monitoring increases sensitivity in detecting abnormal esophageal acid exposure. J Gastrointest Surg 2005; 9:1043–1052.

42 42 Scarpulla G, Camilleri S, Galante P, et al. The impact of prolonged pH measurements on the diagnosis of gastroesophageal reflux disease: 4–day wireless pH studies. Am J Gastroenterol 2007; 102:2642–2647.

43 43 Hirano I, Zhang Q, Pandolfino JE, et al. Four‐day bravo pH capsule monitoring with and without proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2005; 3:1083–1088.

44 44 Savarino E, Bredenoord AJ, Fox M, et al. Expert consensus document: Advances in the physiological assessment and diagnosis of GERD. Nat Rev Gastroenterol Hepatol 2017; 14:665–676.

45 45 Hemmink GJM, Bredenoord AJ, Weusten BLAM, et al. Esophageal pH‐impedance monitoring in patients with therapy‐resistant reflux symptoms: ‘On’ or ‘Off’ proton pump inhibitor? Am J Gastroenterol 2008; 103:2446–2453.

46 46 Mainie I, Tutuian R, Shay S, et al. Acid and non‐acid reflux in patients with persistent symptoms despite acid suppressive therapy: A multicentre study using combined ambulatory impedance‐pH monitoring. Gut 2006; 55:1398–1402.

47 47 Zerbib F, Roman S, Ropert A, et al. Esophageal pH‐impedance monitoring and symptom analysis in GERD: A study in patients off and on therapy. Am J Gastroenterol 2006; 101:1956–1963.

48 48 Kondo T, Miwa H. The role of esophageal hypersensitivity in functional heartburn. J Clin Gastroenterol 2017; 51:571–578.

49 49 Knowles CH, Aziz Q. Visceral hypersensitivity in non‐erosive reflux disease. Gut 2008; 57:674–683.

50 50 Knowles CH, Aziz Q. Basic and clinical aspects of gastrointestinal pain. Pain 2009; 141:191–209.

51 51 Hobson AR, Furlong PL, Sarkar S, et al. Neurophysiologic assessment of esophageal sensory processing in non‐cardiac chest pain. Gastroenterology 2006; 130:80–88.

52 52 Rao SSC, Gregersen H, Hayek B, et al. Unexplained chest pain: the hypersensitive, hyperreactive, and poorly compliant esophagus. Ann Intern Med 1996; 124:950.

53 53 Balaban DH, Yamamoto Y, Liu J, et al. Sustained esophageal contraction: A marker of esophageal chest pain identified by intraluminal ultrasonography. Gastroenterology 1999; 116:29–37.

54 54 Pehlivanov N, Liu J, Mittal RK. Sustained esophageal contraction: a motor correlate of heartburn symptom. Am J Physiol Liver Physiol 2001; 281:G743–G751.

55 55 Bhalla V, Liu J, Puckett JL, et al. Symptom hypersensitivity to acid infusion is associated with hypersensitivity of esophageal contractility. Am J Physiol Liver Physiol 2004; 287:G65–G71.

56 56 McIntosh K, Paterson WG. Sustained esophageal longitudinal smooth muscle contraction may not be a cause of noncardiac chest pain. Neurogastroenterol Motil 2018; 30:1–6.

57 57 Yang M, Li Z, Chen D, et al. Quantitative assessment and characterization of visceral hyperalgesia evoked by esophageal balloon distention and acid perfusion in patients with functional heartburn, nonerosive reflux disease, and erosive esophagitis. Clin J Pain 2010; 26:326–331.

58 58 Holzer P. Acid‐sensing ion channels in gastrointestinal function. Neuropharmacology 2015; 94:72–79.

59 59 Holzer P. Acid sensing by visceral afferent neurones. Acta Physiol 2011; 201:63–75.

60 60 Galligan J. Actions of sumatriptan on myenteric neurones: relief from an old headache in the enteric nervous system? Neurogastroenterol Motil 2007; 19:1–3.

61 61 Yu S, Undem BJ, Kollarik M. Vagal afferent nerves with nociceptive properties in guinea‐pig oesophagus. J Physiol 2005; 563:831–842.

62 62 Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: A unifying hypothesis. Gastroenterology 2005; 128:771–778.

63 63 Tobey N, Hosseini S, Argote C, et al. Dilated intercellular spaces and shunt permeability in non‐erosive acid‐damaged esophageal epithelium. Am J Gastroenterol 2004; 99:13–22.

64 64 Tobey N. The role of pepsin in acid injury to esophageal epithelium. Am J Gastroenterol 2001; 96:3062–3070.

65 65 Zhang S, Owyang C, Liu Z, et al. Intraluminal acid activates esophageal nodose C fibers after mast cell activation. Am J Physiol Liver Physiol 2013; 306:G200–G207.

66 66 Groschwitz KR, Wu D, Osterfeld H, et al. Chymase‐mediated intestinal epithelial permeability is regulated by a protease‐activating receptor/matrix metalloproteinase‐2–dependent mechanism. Am J Physiol Liver Physiol 2013; 304:G479–G489.

67 67 Groschwitz KR, Ahrens R, Osterfeld H, et al. Mast cells regulate homeostatic intestinal epithelial migration and barrier function by a chymase/Mcpt4–dependent mechanism. Proc Natl Acad Sci 2009; 106:22381–22386.

68 68 Scudamore CL. Release of the mucosal mast cell granule chymase, rat mast cell protease‐II, during anaphylaxis is associated with the rapid development of paracellular permeability to macromolecules in rat jejunum. J Exp Med 1995; 182:1871–1881.

69 69 Snoek SA, Dhawan S, van Bree SH, et al. Mast cells trigger epithelial barrier dysfunction, bacterial translocation and postoperative ileus in a mouse model. Neurogastroenterol Motil 2012; 24:172–e91.

70 70 Souza RF, Huo X, Mittal V, et al. Gastroesophageal reflux might cause esophagitis through a cytokine‐mediated mechanism rather than caustic acid Injury. Gastroenterology 2009; 137:1776–1784.

71 71 Wu L, Oshima T, Shan J, et al. PAR‐2 activation enhances weak acid‐induced ATP release through TRPV1 and ASIC sensitization in human esophageal epithelial cells. Am J Physiol Liver Physiol 2015; 309:G695–G702.

72 72 Kondo T, Oshima T, Tomita T, et al. Prostaglandin E 2 mediates acid‐induced heartburn in healthy volunteers. Am J Physiol Liver Physiol 2013; 304:G568–G573.

73 73 Sei H, Oshima T, Shan J, et al. Correction: Esophageal epithelial‐derived IL‐33 Is upregulated in patients with heartburn. PLoS One 2016; 11:e0158932.

74 74 Yoshida N, Imamoto E, Uchiyama K, et al. Molecular mechanisms involved in interleukin‐8 production by normal human oesophageal epithelial cells. Aliment Pharmacol Ther 2006; 24:219–226.

75 75 Huo X, Souza RF. Acid burn or cytokine sizzle in the pathogenesis of heartburn? J Gastroenterol Hepatol 2013; 28:385–387.

76 76 Willert RP, Woolf CJ, Hobson AR, et al. The development and maintenance of human visceral pain hypersensitivity is dependent on the N‐methyl‐d‐aspartate receptor. Gastroenterology 2004; 126:683–692.

77 77 Willert RP, Delaney C, Kelly K, et al. Exploring the neurophysiological basis of chest wall allodynia induced by experimental oesophageal acidification ? evidence of central sensitization. Neurogastroenterol Motil 2007; 19:270–278.

78 78 Banerjee B, Medda BK, Zheng Y, et al. Alterations in N‐methyl‐d‐aspartate receptor subunits in primary sensory neurons following acid‐induced esophagitis in cats. Am J Physiol Liver Physiol 2009; 296:G66–G77.

79 79 Hubscher CH, Kaddumi EG, Johnson RD. Brain stem convergence of pelvic viscerosomatic inputs via spinal and vagal afferents. Neuroreport 2004; 15:1299–1302.

80 80 Farmer AD, Ruffle JK, Aziz Q. The role of esophageal hypersensitivity in functional esophageal disorders. J Clin Gastroenterol 2017; 51:91–99.

81 81 Giamberardino MA, Costantini R, Affaitati G, et al. Viscero‐visceral hyperalgesia: Characterization in different clinical models. Pain 2010; 151:307–322.

82 82 Fass R, Naliboff BD, Fass SS, et al. The effect of auditory stress on perception of intraesophageal acid in patients with gastroesophageal reflux disease. Gastroenterology 2008; 134:696–705.

83 83 Wright CE, Ebrecht M, Mitchell R, et al. The effect of psychological stress on symptom severity and perception in patients with gastro‐oesophageal reflux. J Psychosom Res 2005; 59:415–424.

84 84 Naliboff BD, Mayer M, Fass R, et al. The effect of life stress on symptoms of heartburn. Psychosom Med 2004; 66:426–434.

85 85 Guadagnoli L, Yadlapati RH, Taft T, et al. Esophageal hypervigilance and symptom anxiety are prevalent across gastroesophageal reflux disease phenotypes. Gastroenterology 2019; 156:S‐52.

86 86 Broers C, Melchior C, Van Oudenhove L, et al. The effect of intravenous corticotropin‐releasing hormone administration on esophageal sensitivity and motility in health. Am J Physiol Liver Physiol 2017; 312:G526–G534.

87 87 Vanuytsel T, van Wanrooy S, Vanheel H, et al. Psychological stress and corticotropin‐releasing hormone increase intestinal permeability in humans by a mast cell‐dependent mechanism. Gut 2014; 63:1293–1299.

88 88 Rodiño‐Janeiro BK, Alonso‐Cotoner C, Pigrau M, et al. Role of corticotropin‐releasing factor in gastrointestinal permeability. J Neurogastroenterol Motil 2015; 21:033–050.

89 89 Lee H, Kim JH, Min B‐H, et al. Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: A randomized, double‐Bbind, placebo‐controlled, crossover trial. Am J Gastroenterol 2010; 105:1504–1512.

90 90 Doraiswamy PM, Varia I, Hellegers C, et al. A randomized controlled trial of paroxetine for non‐cardiac chest pain. Psychopharmacol Bull 2006; 39:15–24.

91 91 Broekaert D, Fischler B, Sifrim D, et al. Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double‐blind, placebo‐controlled study. Aliment Pharmacol Ther 2006; 23:365–370.

92 92 Varia I, Logue E, O’Connor C, et al. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J 2000; 140:367–372.

93 93 Keefe FJ, Shelby RA, Somers TJ, et al. Effects of coping skills training and sertraline in patients with non‐cardiac chest pain: A randomized controlled study. Pain 2011; 152:730–741.

94 94 Spinhoven P, Van der Does AJW, Van Dijk E, et al. Heart‐focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive‐behavioral therapy and paroxetine. J Psychosom Res 2010; 69:227–235.

95 95 Cannon ROI, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994; 330:1411–1417.

96 96 Prakash C, Clouse RE. Long‐term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci 1999; 44:2373–2379.

97 97 Clouse RE, Lustman PJ, Eckert TC, et al. Low‐dose trazodone for symptomatic patients with esophageal contraction abnormalities. Gastroenterology 1987; 92:1027–1036.

98 98 Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci 2002; 99:8921–8926.

99 99 Rao SSC, Mudipalli RS, Mujica V, et al. An open‐label trial of theophylline for functional chest pain. Dig Dis Sci 2002; 47:2763–2768.

100 100 Rao SSC, Mudipalli RS, Remes‐Troche JM, et al. Theophylline improves esophageal chest pain? A randomized, placebo‐controlled study. Am J Gastroenterol 2007; 102:930–938.

101 101 Hu Y, Yu X, Yu S. QX‐314 inhibits acid‐induced activation of esophageal nociceptive C fiber neurons. Neurogastroenterol Motil 2019:1–7.

102 102 Yeh JZ. Sodium inactivation mechanism modulates QX‐314 block of sodium channels in squid axons. Biophys J 1978; 24:569–574.

103 103 Connors BW, Prince DA. Effects of local anesthetic QX‐314 on the membrane properties of hippocampal pyramidal neurons. J Pharmacol Exp Ther 1982; 220:476–481.

104 104 Binshtok AM, Bean BP, Woolf CJ. Inhibition of nociceptors by TRPV1–mediated entry of impermeant sodium channel blockers. Nature 2007; 449:607–610.

105 105 Talbot S, Abdulnour R‐EE, Burkett PR, et al. Silencing Nociceptor Neurons Reduces Allergic Airway Inflammation. Neuron 2015; 87:341–354.

106 106 Keefer L, Palsson OS, Pandolfino JE. Best practice update: incorporating psychogastroenterology into management of digestive disorders. Gastroenterology 2018; 154:1249–1257.

107 107 Klimes I, Mayou RA, Pearce MJ, et al. Psychological treatment for atypical non‐cardiac chest pain: a controlled evaluation. Psychol Med 1990; 20:605–611.

108 108 Mayou R, Bryant B, Sanders D, et al. A controlled trial of cognitive behavioural therapy for non‐cardiac chest pain. Psychol Med 1997; 27:S0033291797005254.

109 109 Potts SG. Group psychological treatment for chest pain with normal coronary arteries. QJM 1999; 92:81–86.

110 110 van Peski‐Oosterbaan AS, Spinhoven P, van Rood Y, et al. Cognitive‐behavioral therapy for noncardiac chest pain: a randomized trial. Am J Med 1999; 106:424–429.

111 111 Jonsbu E, Dammen T, Morken G, et al. Short‐term cognitive behavioral therapy for non‐cardiac chest pain and benign palpitations: A randomized controlled trial. J Psychosom Res 2011; 70:117–123.

112 112 van Beek MHCT, Oude Voshaar RC, Beek AM, et al. A brief cognitive‐behaviroal intervention for treating depression and panic disorder in patients with noncardiac chest pain: a 24–week randomized controlled trialz. Depress Anxiety 2013; 30:670–678.

113 113 Shapiro M, Shanani R, Taback H, et al. Functional chest pain responds to biofeedback treatment but functional heartburn does not. Eur J Gastroenterol Hepatol 2012; 24:708–714.

114 114 Jones H. Treatment of non‐cardiac chest pain: a controlled trial of hypnotherapy. Gut 2006; 55:1403–1408.

115 115 Johrei OM. Divine light of salvation. 1st ed. Kyoto, Japan: Society of Johrei; 1984.

116 116 Gasiorowska A, Navarro‐Rodriguez T, Dickman R, et al. Clinical trial: The effect of Johrei on symptoms of patients with functional chest pain. Aliment Pharmacol Ther 2009; 29:126–134.

117 117 Kisely SR, Campbell LA, Yelland MJ, et al. Psychological interventions for symptomatic management of non‐specific chest pain in patients with normal coronary anatomy. Cochrane Database Syst Rev June 2015.

118 118 Walmart, $4 prescription list, https://www.walmart.com/cp/$4–prescriptions/1078664.

119 119 GoodRx, Imipramine, https://www.goodrx.com/imipramine‐hydrochloride.

120 120 Milavetz G, Vaughan LM, Weinberger MM, et al. Evaluation of a scheme for establishing and maintaining dosage of theophylline in ambulatory patients with chronic asthma. J Pediatr 1986; 109:351–354.

121 121 Skinner MH. Adverse reactions and interactions with theophylline. Drug Saf 1990; 5:275–285.

122 122 Sadowski DC, Ackah F, Jiang B, et al. Achalasia: incidence, prevalence and survival. A population‐based study. Neurogastroenterol Motil 2010; 22:e256–e261.

123 123 Roman S, Huot L, Zerbib F, et al. High‐resolution manometry improves the diagnosis of esophageal motility disorders in patients with dysphagia: A randomized multicenter study. Am J Gastroenterol 2016; 111:372–380.

124 124 Rohof WOA, Bredenoord AJ. Chicago classification of esophageal motility disorders: Lessons Learned. Curr Gastroenterol Rep 2017; 19:1–6.

125 125 Goldblum J, Rice T, Richter J. Histopathologic features in esophagomyotomy specimens from patients with achalasia. Gastroenterology 1996; 111:648–654.

126 126 Clark SB, Rice TW, Tubbs RR, et al. The nature of the myenteric infiltrate in achalasia. Am J Surg Pathol 2000; 24:1153–1158.

127 127 Villanacci V, Annese V, Cuttitta A, et al. An immunohistochemical study of the myenteric plexus in idiopathic achalasia. J Clin Gastroenterol 2010; 44:407–410.

128 128 Kilic A, Owens SR, Pennathur A, et al. An increased proportion of inflammatory cells express tumor necrosis factor alpha in idiopathic achalasia of the esophagus. Dis Esophagus 2009; 22:382–385.

129 129 Storch WB, Eckardt VF, Junginger T. Complement components and terminal complement complex in oesophageal smooth muscle of patients with achalasia. Cell Mol Biol (Noisy‐le‐grand) 2002; 48:247–252.

130 130 Verne GN, Hahn AB, Pineau BC, et al. Association of HLA‐DR and ‐DQ alleles with idiopathic achalasia. Gastroenterology 1999; 117:26–31.

131 131 Verne GN, Sallustio JE, Eaker EY. Anti‐myenteric neuronal antibodies in patients with achalasia. A prospective study. Dig Dis Sci 1997; 42:307–313.

132 132 Niwamoto H, Okamoto E, Fujimoto J, et al. Are human herpes viruses or measles virus associated with esophageal achalasia? Dig Dis Sci 1995; 40:859–864.

133 133 Birgisson S, Galinski MS, Goldblum JR, et al. Achalasia is not associated with measles or known herpes and human papilloma viruses. Dig Dis Sci 1997; 42:300–306.

134 134 Facco M, Brun P, Baesso I, et al. T cells in the myenteric plexus of achalasia patients show a skewed TCR repertoire and react to HSV‐1 Antigens. Am J Gastroenterol 2008; 103:1598–1609.

135 135 Robertson CS, Martin BAB, Atkinson M. Varicella‐zoster virus DNA in the oesophageal myenteric plexus in achalasia. Gut 1993; 34:299–302.

136 136 Castagliuolo I. Esophageal achalasia: Is the herpes simplex virus really innocent? J Gastrointest Surg 2004; 8:24–30.

137 137 Jeon HH, Kim J‐H, Youn YH, et al. Clinical characteristics of patients with untreated achalasia. J Neurogastroenterol Motil 2017; 23:378–384.

138 138 Jung DH, Park H. Is Gastroesophageal reflux disease and achalasia coincident or not? J Neurogastroenterol Motil 2017; 23:5–8.

139 139 Massey BT, Hogan WJ, Dodds WJ, et al. Alteration of the upper esophageal sphincter belch reflex in patients with achalasia. Gastroenterology 1992; 103:1574–1579.

140 140 Howard PJ, Maher L, Pryde A, et al. Five year prospective study of the incidence, clinical features, and diagnosis of achalasia in Edinburgh. Gut 1992; 33:1011–1015.

141 141 Eckardt VF, Aignherr C, Bernhard G. Predictors of outcome in patients with achalasia treated by pneumatic dilation. Gastroenterology 1992; 103:1732–1738.

142 142 Achem SR, Gerson LB. Distal esophageal spasm: An update. Curr Gastroenterol Rep 2013; 15:7–15.

143 143 Pandolfino JE, Roman S, Carlson D, et al. Distal esophageal spasm in high‐resolution esophageal pressure topography: defining clinical phenotypes. Gastroenterology 2011; 141:469–475.

144 144 Konturek JW, Gillessen A, Domschke W. Diffuse esophageal spasm: a malfunction that involves nitric oxide? Scand J Gastroenterol 1995; 30:1041–1045.

145 145 Murray JA, Ledlow A, Launspach J, et al. The effects of recombinant human hemoglobin on esophageal motor function in humans. Gastroenterology 1995; 109:1241–1248.

146 146 Samo S, Carlson DA, Kahrilas PJ, et al. Ineffective esophageal motility progressing into distal esophageal spasm and then type III achalasia. ACG Case Reports J 2016; 3:e183.

147 147 De Schepper HU, Smout AJPM, Bredenoord AJ. Distal esophageal spasm evolving to achalasia in high resolution. Clin Gastroenterol Hepatol 2014; 12:A25–A26.

148 148 Jia Y, Arenas J, Hejazi RA, et al. Frequency of jackhammer esophagus as the extreme phenotype of esophageal hypercontractility based on the new Chicago Classification. J Clin Gastroenterol 2016; 50:615–618.

149 149 Roman S, Pandolfino JE, Chen J, et al. Phenotypes and clinical context of hypercontractility in high‐resolution esophageal pressure topography (EPT). Am J Gastroenterol 2012; 107:37–45.

150 150 Loo FD, Dodds WJ, Soergel KH, et al. Multipeaked esophageal peristaltic pressure waves in patients with diabetic neuropathy. Gastroenterology 1985; 88:485–491.

151 151 Jung H‐Y, Puckett JL, Bhalla V, et al. Asynchrony between the circular and thelongitudinal muscle contraction in patients with Nutcracker Esophagus. Gastroenterology 2005; 128:1179–1186.

152 152 Richter JE, Dalton CB, Bradley LA, et al. Oral nifedipine in the treatment of noncardiac chest pain in patients with the nutcracker esophagus. Gastroenterology 1987; 93:21–28.

153 153 Cattau EL, Castell DO, Johnson DA, et al. Diltiazem therapy for symptoms associated with nutcracker esophagus. Am J Gastroenterol 1991; 86:272–276.

154 154 Traube M. Effects of nifedipine in achalasia and in patients with high‐amplitude peristaltic esophageal contractions. JAMA 1984; 252:1733.

155 155 Drenth J, Bos L, Engels L. Efficacy of diltiazem in the treatment of diffuse oesophageal spasm. Aliment Pharmacol Ther 1990; 4:411–416.

156 156 Davies A, Lewis MJ, Rhodes J, et al. Trial of Nifedipine for prevention of oesophageal spasm. Digestion 1987; 36:81–83.

157 157 Swamy N. Esophageal spasm: clinical and manometric response to nitroglycerine and long acting nitrites. Gastroenterology 1977; 72:23–27.

158 158 Orlando RC, Bozymski EM. Clinical and manometric effects of nitroglycerin in diffuse esophageal spasm. N Engl J Med 1973; 289:23–25.

159 159 Wen Z, Gardener E, Wang Y. Nitrates for achalasia. Cochrane Database Syst Rev 2004; 1:CD002299.

160 160 Roman S, Kahrilas PJ. Management of spastic disorders of the esophagus. Gastroenterol Clin North Am 2013; 42:27–43.

161 161 Bortolotti M, Mari C, Lopilato C, et al. Effects of sildenafil on esophageal motility of patients with idiopathic achalasia. Gastroenterology 2000; 118:253–257.

162 162 Eherer AJ. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut 2002; 50:758–764.

163 163 Pimentel M, Bonorris GG, Chow EJ, et al. Peppermint oil improves the manometric findings in diffuse esophageal spasm. J Clin Gastroenterol 2001; 33:27–31.

164 164 Khalaf MHG, Chowdhary S, Elmunzer BJ, et al. Impact of peppermint therapy on dysphagia and non‐cardiac chest pain: A Pilot Study. Dig Dis Sci 2019; 64(8):2414–18.

165 165 Pandolfino JE, Kwiatek MA, Nealis T, et al. Achalasia: a new clinically relevant classification by high‐resolution manometry. Gastroenterology 2008; 135:1526–1533.

166 166 Ebert EC, Ouyang A, Wright SH, et al. Pneumatic dilatation in patients with symptomatic diffuse esophageal spasm and lower esophageal sphincter dysfunction. Dig Dis Sci 1983; 28:481–485.

167 167 Pasricha P, Rai R, Ravich W, et al. Botulinum toxin for achalasia: Long‐term outcome and predictors of response. Gastroenterology 1996; 110:1410–1415.

168 168 Cuilliere C, Ducrotte P, Zerbib F, et al. Achalasia: outcome of patients treated with intrasphincteric injection of botulinum toxin. Gut 1997; 41:87–92.

169 169 Shaheen NJ, Falk GW, Iyer PG, et al. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016; 111:30–50.

170 170 Fishman V, Parkman H, Schiano T, et al. Symptomatic improvement in achalasia after botulinum toxin injection of the lower esophageal sphincter. Am J Gastroenterol 1996; 91:1724–1730.

171 171 Storr M, Allescher H‐D, Rösch T, et al. Treatment of symptomatic diffuse esophageal spasm by endoscopic injections of botulinum toxin: A prospective study with long‐term follow‐up. Gastrointest Endosc 2001; 54:754–759.

172 172 Wang L, Li Y‐M, Li L. Meta‐Analysis of randomized and controlled treatment trials for achalasia. Dig Dis Sci 2009; 54:2303–2311.

173 173 Yaghoobi M, Mayrand S, Martel M, et al. Laparoscopic Heller’s myotomy versus pneumatic dilation in the treatment of idiopathic achalasia: a meta‐analysis of randomized, controlled trials. Gastrointest Endosc 2013; 78:468–475.

174 174 Boeckxstaens GE, Annese V, Varannes SB des, et al. Pneumatic dilation versus laparoscopic Heller myotomy for idiopathic achalasia. N Engl J Med 2011; 364:1807–1816.

175 175 Yuan X‐L, Liu W, Ye L‐S, et al. Peroral endoscopic dual myotomy (dual POEM) for achalasia with severe esophageal dilatation. Endoscopy 2018; 50:E179–E180.

176 176 Kumbhari V, Tieu A, Onimaru M, et al. Peroral endoscopic myotomy (POEM) vs laparoscopic Heller myotomy (LHM) for the treatment of Type III achalasia in 75 patients: a multicenter comparative study. Endosc Int Open 2015; 3:E195–E201.

177 177 Khashab MA, Benias PC, Swanstrom LL. Endoscopic myotomy for foregut motility disorders. Gastroenterology 2018; 154:1901–1910.

178 178 Ujiki MB, Yetasook AK, Zapf M, et al. Peroral endoscopic myotomy: A short‐term comparison with the standard laparoscopic approach. Surgery 2013; 154:893–900.

179 179 Youn YH, Minami H, Chiu PWY, et al. Peroral endoscopic myotomy for treating achalasia and esophageal motility disorders. J Neurogastroenterol Motil 2015; 22:14–24.

180 180 Shiwaku H, Inoue H, Beppu R, et al. Successful treatment of diffuse esophageal spasm by peroral endoscopic myotomy. Gastrointest Endosc 2013; 77:149–150.

181 181 Albers D, Frieling T, Dakkak D, et al. Peroral endoscopic myotomy (POEM) is effective in treatment of noncardiac chest pain caused by hypercontractile esophageal motility disorders: results of the POEM‐HYPE‐Study. Z Gastroenterol 2018; 56:1337–1342.

182 182 Filicori F, Dunst CM, Sharata A, et al. Long‐term outcomes following POEM for non‐achalasia motility disorders of the esophagus. Surg Endosc Other Interv Tech 2018; 0:0.

183 183 Khan MA, Kumbhari V, Ngamruengphong S, et al. Is POEM the answer for management of spastic esophageal disorders? a systematic review and meta‐analysis. Dig Dis Sci 2017; 62:35–44.

184 184 Ponds FA, Fockens P, Lei A, et al. Effect of peroral endoscopic myotomy vs pneumatic dilation on symptom severity and treatment outcomes among treatment‐naive patients with achalasia. JAMA 2019; 322:134.

185 185 Kumbhari V, Familiari P, Bjerregaard N, et al. Gastroesophageal reflux after peroral endoscopic myotomy: a multicenter case‐control study. Endoscopy 2017; 49:634–642.

186 186 Schlottmann F, Luckett DJ, Fine J, et al. Laparoscopic Heller myotomy versus peroral endoscopic myotomy (POEM) for achalasia. Ann Surg 2018; 267:451–460.

187 187 Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013; 108:308–328.